Shanghai Pharmaceuticals: Plans to publicly list and transfer 30% equity of Bristol-Myers Squibb

2026-02-14 07:32:18

Shanghai Pharmaceuticals announces its plan to transfer a 30% stake in Bristol-Myers Squibb through a public listing on the property rights exchange, with a minimum listing price of 1.023 billion RMB. This transaction does not constitute a related-party transaction or a major asset restructuring. The transaction has been approved by the 28th meeting of the company’s eighth board of directors and does not require shareholder approval. The transaction is still subject to the public listing procedures of the property rights exchange, and the acquirer and final transaction price have not yet been determined.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.